Clinical Trials · NCT05086614
Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Fudan University
- Enrollment
- 2,500
- Start date
- Apr 2021
- Locations
- 1 site, China
- Primary endpoint
- 3-year disease-free survival rate